Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.71 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.71 |
| ▸ | PLAU | P00749 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PLK1 | P53350 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2296845 | 0.85 | HDAC6 (0.51) | HDAC6HDAC1PLAUHDAC8HDAC2 | |
| SCHEMBL18642563 | 0.83 | HDAC1 (0.73) | HDAC6HDAC1CTSLCTSSCTSK | |
| SCHEMBL28815880 | 0.83 | HDAC6 (1.00) | HDAC6HDAC1HDAC8CTSLCTSS | |
| SCHEMBL940919 | 0.82 | PLAU (0.53) | HDAC6HDAC1PLAUHDAC8HDAC2 | |
| SCHEMBL29582662 | 0.82 | PLAU (0.53) | HDAC6HDAC1PLAUHDAC8HDAC2 | |
| SCHEMBL30147734 | 0.82 | CES2 (0.59) | HDAC6HDAC1PLAUHDAC8HDAC2 | |
| SCHEMBL531941 | 0.82 | CES2 (0.59) | HDAC6HDAC1PLAUHDAC8HDAC2 | |
| SCHEMBL10093232 | 0.81 | HDAC1 (0.65) | HDAC6HDAC1CTSLCTSSCTSK | |
| SCHEMBL1441177 | 0.79 | HDAC6 (0.73) | HDAC6HDAC1PLAUHDAC8HDAC2 | |
| SCHEMBL8515075 | 0.79 | ESRRG (0.50) | HDAC6HDAC1PLAUHDAC8HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2906559-B1 | AZAINDOLINES | HOFFMANN LA ROCHE (CH) | 2017-02-08 | — | — | EP | claimed |
| US-9309248-B2 | Azaindolines | HOFFMANN-LA ROCHE INC. (US) | 2016-04-12 | — | — | US | claimed |
| US-20150266879-A1 | AZAINDOLINES | HOFFMANN-LA ROCHE INC. | 2015-09-24 | — | — | US | claimed |
| EP-2906559-A1 | AZAINDOLINES | F. Hoffmann-La Roche AG (CH) | 2015-08-19 | — | — | EP | claimed |
| WO-2014056871-A1 | AZAINDOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-04-17 | — | — | WO | claimed |
| US-20260103455-A1 | ULK3 INHIBITORS AND USES THEREOF | H LEE MOFFITT CANCER CT & RES (US) | 2026-04-16 | — | — | US | disclosed |
| EP-4676602-A1 | COMPOUNDS TARGETING MUTATIONS IN P53 AND USES THEREOF | Merck Sharp & Dohme LLC (US) | 2026-01-14 | — | — | EP | disclosed |
| EP-4640678-A1 | NOVEL OXO-PYRIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | Chengdu Shibeikang Biomedical Technology Co., Ltd. (CN) | 2025-10-29 | — | — | EP | disclosed |
| EP-4605392-A1 | METHODS FOR TREATING CANCER | Antares Therapeutics, Inc. (US) | 2025-08-27 | — | — | EP | disclosed |
| WO-2025059074-A1 | BICYCLIC COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV PHARMACEUTICALS, INC. (US) | 2025-03-20 | — | — | WO | disclosed |
| CN-116082303-B | Novel oxopyridines, intermediates and uses thereof | 成都施贝康生物医药科技有限公司 | 2025-02-25 | — | — | CN | disclosed |
| WO-2024187153-A1 | COMPOUNDS TARGETING MUTATIONS IN P53 AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-09-12 | — | — | WO | disclosed |
| EP-2298747-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2011-03-23 | — | — | EP | disclosed |
| WO-2010001946-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | アステラス製薬株式会社 (JP) | 2010-01-07 | — | — | WO | disclosed |
| WO-2009153197-A1 | HALO-SUBSTITUTED PYRIMIDODIAZEPINES AS PLKL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-23 | — | — | WO | disclosed |
| WO-2007120752-A2 | 4, 5-DIHYDRO- [1, 2, 4] TRIAZOLO [4, 3-F] PTERIDINES AS PROTEIN KINASE PLK1 INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-25 | — | — | WO | disclosed |
| EP-1467965-A1 | N-(4-SUBSTITUTED PHENYL)-ANTHRANILIC ACID HYDROXAMATE ESTERS | Warner-Lambert Company LLC (US) | 2004-10-20 | — | — | EP | disclosed |
| US-6770778-B2 | MAP KINASE INHIBITORS; ANTICARCINOGENIC AGENTS; RESTENOSIS, PSORIASIS, AND ATHEROSCLEROSIS TREATMENT; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS | PFIZER INC | 2004-08-03 | — | — | US | disclosed |
| US-20030232889-A1 | N-(4-substituted phenyl)-anthranilic acid hydroxamate esters | WARNET-LAMBERT COMPANY LLC | 2003-12-18 | — | — | US | disclosed |
| WO-2003062189-A1 | N-(4-SUBSTITUTED PHENYL)-ANTHRANILIC ACID HYDROXAMATE ESTERS | WARNER-LAMBERT COMPANY LLC (US) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232889-A1 | N-(4-substituted phenyl)-anthranilic acid hydroxamate esters | AADAC, EGLN3, HCAR2 | HDAC6 297/4885HDAC1 355/4885PLAU 1587/4885 |
| US-20150266879-A1 | AZAINDOLINES | AZI2, H1-5, CCNY | HDAC6 100/4885HDAC1 16/4885PLAU 4562/4885 |
| US-20260103455-A1 | ULK3 INHIBITORS AND USES THEREOF | ULK3, ULK1, ULK2 | HDAC6 785/4885HDAC1 1145/4885PLAU 1911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.